In today's complicated world, there are many different women and many different birth control options! Moreover, women's needs and wants concerning contraception have changed.

The benefits that ParaGard® offers today's women make it an appealing contraceptive option for many patients.

So who are some of these women?
Roll over the following captions to see who might be candidates for ParaGard®.

 

Potential ParaGard® Candidates:

  • Women who want to avoid hormonal side effects such as weight gain
  • Breastfeeding women who don't want to use hormones
  • Women who prefer to have their natural monthly cycle

back to top

  • Women with medical conditions such as uncontrolled diabetes, hypertension, or breast cancer1
  • Women over 35 who smoke1

back to top

  • Women who want long-term but easily reversible contraception
  • Women seeking an alternative to sterilization

back to top

  • Women who need birth control to carry them through to menopause
  • Women who have been on hormones for years and want to try a nonhormonal birth control option

back to top

ParaGard® does not protect against HIV/AIDS or other sexually transmitted infections. ParaGard® must not be used by women who are or may be pregnant; have acute pelvic inflammatory disease (PID) or current behavior suggesting a high risk for PID; have had a postpregnancy or postabortion uterine infection in the past 3 months; have cancer of the uterus or cervix; have an infection in the cervix; have an allergy to any component; or have Wilson's disease. The most common side effects of ParaGard® are heavier and longer periods and spotting between periods; for most women, these typically subside after 2 to 3 months. If a woman misses her period, she must be promptly evaluated for pregnancy. Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard®, are PID, perforation of the uterus, and expulsion.

References:

Reference:

  1. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva, Switzerland: World Health Organization, Reproductive Health and Research; 2004.